Imaging of hypoxia with [18F] fluoromisonidazole for cure limitation tissue and therapy strategy
Not Applicable
- Conditions
- ung cancer, Breast cancer, Colon cancer, Head and neck cancer, Brain tumor, Pancreatic cancer, Malignant lymphoma, Malignant melanoma, Esophageal cancer, Endometrial cancer,uterine cervical cancer, ovarian cancer
- Registration Number
- JPRN-UMIN000002652
- Lead Sponsor
- Saitama Medical University
- Brief Summary
We evaluated a metabolic variation of tumors using positron emission tomography. Various metabolic patterns were demonstrated in our studies, and these results should be useful for diagnosis and therapy of various malignant tumors. An early response to radiation and/or chemotherapy was evaluated based on tumor shrinkage using CT images. The FMISO uptake in the tumor had a negative correlation with the tumor shrinkage after therapy. FMISO may be a good predictive indicator for therapy. Breast cancer showed various metabolic patterns, which may correlate with the intrinsic subtypes.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
Pregnancy or possibility of pregnancy Patients regarded as unsuitable by responsible investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Tracer uptake in biphasic pairs of [18F]FMISO-PET/CT and [18F]FDG-PET/CT
- Secondary Outcome Measures
Name Time Method